Kaken Pharmaceutical Co., Ltd. (KKPCF)
OTCMKTS
· Delayed Price · Currency is USD
26.78
+26.78 (0.00%)
Jan 31, 2025, 4:00 PM EDT
Kaken Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Kaken Pharmaceutical had annual revenue of 94.04B JPY with 30.52% growth. Kaken Pharmaceutical had revenue of 18.05B in the quarter ending March 31, 2025, with 3.95% growth.
Revenue
94.04B JPY
Revenue Growth
+30.52%
P/S Ratio
1.58
Revenue / Employee
82.85M JPY
Employees
1,135
Market Cap
989.15M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 94.04B | 21.99B | 30.52% |
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Kaken Pharmaceutical News
- 2 months ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 7 months ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga